Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

Hypercortisolism (Cushing syndrome)

Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients

Steffensen et al • 2019 • Horm Metab Res.

Hypercortisolism (Cushing syndrome)

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Pivonello et al • 2021 • Front. Endocrinol., 14 July 2021

Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer

Munster et al. • 2019 •

Hypercortisolism (Cushing syndrome)

Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism

Pivonello et al. • 2019 • American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress

Hypercortisolism (Cushing syndrome)

Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis

Elhassan et al • 2019 • Ann Intern Med.

Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.

Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.

Minireview: nuclear receptors and breast cancer.

Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.

Block et al. • 2017 • Cancer Manag Res. 2017;9:65-72.

Steroid receptors aplenty in prostate cancer.

Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.

“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.

Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.